Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
Molecular Weight:
446.9
Purity:
99.56%
CAS Number:
[184475-35-2]
Formula:
C22H24ClFN4O3
Target:
Apoptosis|||EGFR|||Autophagy|||Tyrosine Kinases
T1181
* VAT and and shipping costs not included. Errors and price changes excepted
